Targeting certain UPR components, including IRE1-α, PERK, and ATF6, can alter the adaptive responses of CRC cells to ERS, hence enhancing their sensitivity to chemotherapy and facilitating death1. This evidence concerns the gene EIF2AK3 and colorectal carcinoma.